Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06095583 |
| Consolidated Lead Sponsor | Shanghai Junshi Bioscience Co |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 756 participants (ESTIMATED) |
| Registered Start Date | 2023-11-15 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Harbin Medical University Cancer Hospital | Harbin, China | Open Hospital Dossier -> |
| Xiangya Hospital Central South University | Changsha, China | Open Hospital Dossier -> |
| The Second Affiliated Hospital of Nanchang University | Nanchang, China | Open Hospital Dossier -> |
| The First Hospital of China Medical University | Shenyang, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.